Associations between regorafenib-induced adverse events (AEs) and efficacy in metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.556
Abstract: 556Background: It is occasionally recognized that, in molecular targeted therapy, target-specific AEs can surrogate its efficacy, such as skin toxicities and anti-EGFR antibodies. Because of multikinase inhibitor, regorafenib is involved in various kinds of adverse… read more here.
Keywords: induced adverse; aes efficacy; efficacy; adverse events ... See more keywords